U.S. SEVERE ORAL MUCOSITIS MARKET ANALYSIS

U.S. Severe Oral Mucositis Market, By Drug Type (Palifermin, Amifostine, Chlorhexidine, Sucralfate, Late Phase (Avasopasem and Dusquetide)), By Cause (Chemotherapy and Radiotherapy), By Grade (Grade III and Grade IV), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Published In : Aug 2021
Code : CMI4571
Pages :116
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key players are focusing on inorganic strategies and fund raising, which is expected to drive the market growth during the forecast period.

The key players in the U.S. are focusing on fund raising activities for boosting research and development for the treatment of severe oral mucositis caused due to radiation and chemotherapy in the cancer patients. For instance, in September 2018, Galera Therapeutics, Inc., a company developing novel mechanism-based therapies, announced that the company secured US$ 150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. The existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures also participated.

Key Players

Major players operating in the U.S. severe oral mucositis market are Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group